BIIB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Biogen Inc (BIIB) is not a strong buy for a beginner, long-term investor at this time. Despite some positive developments in its pipeline and analyst optimism about future catalysts, the company's financial performance is weak, with declining revenue and net income. Additionally, insider selling and lack of significant hedge fund activity suggest limited confidence in the stock's near-term performance. The technical indicators and options data also do not indicate a strong upward trend. Therefore, it is better to hold off on investing in BIIB for now.
The technical indicators for BIIB are neutral to slightly bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 45.612, and moving averages are converging. The stock is trading below the pivot level of 190.309, with support at 183.841 and resistance at 196.776. This suggests limited upward momentum in the near term.
Positive data on high-dose nusinersen for spinal muscular atrophy presented at the 2026 Muscular Dystrophy Association conference.
Promising results from Phase 1/2a studies of zorevunersen for Dravet syndrome, showing potential for disease modification.
Insider selling has increased significantly by 864.10% over the last month, indicating a lack of confidence from insiders.
Weak financial performance in Q4 2025, with revenue, net income, and EPS all showing significant declines year-over-year.
Analysts remain cautious about the company's revenue growth trajectory despite some optimism about its pipeline.
In Q4 2025, Biogen's financial performance was weak. Revenue dropped 7.14% YoY to $2.28 billion, net income fell to -$48.9 million (down 118.34% YoY), and EPS declined to -$0.33 (down 118.03% YoY). Gross margin remained stable at 72.46%, but the overall financials highlight challenges in revenue growth and profitability.
Analyst sentiment is mixed. While several analysts raised their price targets following Q4 2025 earnings, ratings range from Neutral to Outperform. Positive factors include better-than-expected EPS guidance and optimism about the pipeline, but concerns about revenue growth persist. Price targets range from $185 to $246, with a median target around $200.
